TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06381934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aSID/ChU Guided Therapy
Description: Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization.
Study: NCT05429216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mEMR-C procedure
Description: A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD procedure
Description: ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
Study: NCT04823585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution. Subcutaneous.
Study: NCT05037240

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Quercetin (500 mg), 2 times a day for 3 months

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg, 2 times a day for 3 months
Study: NCT05245435

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT-PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT-PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: liquid biopsies
Description: circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: liquid biopsies
Description: circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: liquid biopsies
Description: circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: liquid biopsies
Description: circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
Study: NCT06399406

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medi-TBS
Description: The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medi-TBS
Description: The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Medi-TBS
Description: The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
Study: NCT05541458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food as medicine
Description: * Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~* Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~* Increase nutrition literacy.~* Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine.
Study: NCT06334575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
Study: NCT05027594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812 + dexamethasone
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
Study: NCT05025839

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity
Study: NCT05862753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction by Etomidate bolus
Description: General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction by Etomidate bolus
Description: General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
Study: NCT05805631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal Pemetrexed
Study: NCT05502367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-2280 Vaginal Tablet/Insert
Description: Vaginal Tablet
Study: NCT05861076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - Low Dose
Description: 1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - Medium Dose
Description: 2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - High Dose
Description: 3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
Study: NCT04813588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pantomiming
Description: Pantomiming with fluency shaping techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy onset
Description: Easy onset method with breathing exercises
Study: NCT05398744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Exercise Program
Description: At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
Study: NCT04734639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.
Description: Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-EI. Condition with an energy-restriction energy deficit
Description: Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
Study: NCT06253702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: to inhibit cyclooxygenase (COX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: to inhibit cyclooxygenase (COX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: to inhibit cyclooxygenase (COX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: to inhibit cyclooxygenase (COX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orilissa
Description: to suppress hormones 200mg dose 2x per day (all participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orilissa
Description: to suppress hormones 200mg dose 2x per day (all participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orilissa
Description: to suppress hormones 200mg dose 2x per day (all participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orilissa
Description: to suppress hormones 200mg dose 2x per day (all participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 50 mg each morning for add back phase (male participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 50 mg each morning for add back phase (male participants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/day in men to prevent conversion of testosterone to estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/day in men to prevent conversion of testosterone to estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Women will receive oral estradiol 2mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Women will receive oral estradiol 2mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Women will receive oral estradiol 2mg/daily
Study: NCT04715620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
Study: NCT05647135

Intervention type: OTHER
Intervention: Medical food
Description: enteral formulas with different protein composition

Intervention type: OTHER
Intervention: Medical food
Description: enteral formulas with different protein composition
Study: NCT06445543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFeast ENHANCED
Description: The intervention group will initially receive 10 weekly prepared heart-healthy meals from MFeast; Lactation nutritional snack bundles to boost milk supply + structural support for breastfeeding/ pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (medically tailored via study team-crafted virtual grocery store) for 16 more weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFeast Usual Care
Description: Those assigned to the MFeast Usual Care group will receive 10 weekly prepared heart-healthy meals from MFeast.
Study: NCT05482308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: Variant 12.2 mg tafamidis free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: Variant 12.2 mg tafamidis free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Reference)
Description: Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Reference)
Description: Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
Study: NCT05020821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-shot superior trunk block with intravenous dexmedetomidine
Description: During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous superior trunk block
Description: During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
Study: NCT04199221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Innoculation Training (SIT)
Description: 1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Innoculation Training (SIT)
Description: 1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extra attempt
Description: an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra attempt
Description: an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
Study: NCT06285435

Intervention type: DIAGNOSTIC_TEST
Intervention: prothrombin fragment 1+2
Description: Blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: prothrombin fragment 1+2
Description: Blood sample
Study: NCT06380153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: 15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: 15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: 15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
Study: NCT05034367

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Description: Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
Study: NCT05883969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GO-PLAY
Description: The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
Study: NCT05851651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal milk expression and breastfeeding self-efficacy enhancement
Description: A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
Study: NCT05119036

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 44 doses of radiation
Description: Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 54 doses of radiation
Description: Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
Study: NCT04896866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship prospective audit and feedback
Description: Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.